U.S. stock market midday update: Context Therapeutics surged 13.23%, with trading volume skyrocketing, attracting attention due to market volatility

U.S. Stock Market Midday Update Context Therapeutics, up 13.23%, with increased trading volume and no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly, up 1.85%. Based on recent key news: On January 7, Eli Lilly signed a research and development agreement with Nimbus to develop a new oral weight loss drug. This collaboration will drive innovation in obesity treatment for Eli Lilly, resulting in a 1.7% increase in stock price. Source: Reuters On January 6, Eli Lilly reduced the price of Mounjaro in China in response to Novo Nordisk's price cuts. This move aims to solidify market position, benefiting the stock price. Source: Zhitong Finance On January 5, analyst Leerink Partners raised Eli Lilly's target price to $1234, reflecting market confidence in its future growth. Source: MarketWatch The competition in the obesity drug market is intensifying, with innovative drugs gaining attention. Novo Nordisk, up 2.16%. Based on recent key news: On January 5, Novo Nordisk announced the launch of the oral version of Wegovy in the U.S., priced at $149 per month, expanding distribution channels and driving stock price up. This move helps recover market share lost to Eli Lilly. Source: Zhitong Finance On January 4, the Supreme People's Court of China made a favorable ruling on the patent for semaglutide compounds, enhancing Novo Nordisk's confidence in its development in China, pushing the stock price up. Source: Zhitong Finance On January 5, the head of public affairs for Novo Nordisk in the U.S. resigned. Despite the competitive pressure in the market, this event did not have a significant impact on the stock price. Source: Reuters The competition in the weight loss drug market is fierce, with policy support for innovation. Alumis, up 98.83%. Based on recent news: On January 6, Alumis announced significant results from its drug envudeucitinib in a Phase 3 trial for moderate to severe plaque psoriasis. Approximately 65% of patients achieved PASI 90 at 24 weeks, and over 40% achieved PASI 100, demonstrating superior skin clearance and good safety. This news significantly boosted the stock price. Source: Alumis Company Announcement On January 6, Alumis plans to present more results from the ONWARD1 and ONWARD2 trials at an upcoming medical conference and intends to submit a new drug application to the U.S. Food and Drug Administration in the second half of 2026. Investors are optimistic about these upcoming catalysts, further driving up the stock price. Source: Benzinga On January 5, Alumis's stock price rose 8.9% in after-hours trading, as the company plans to announce top-line data from the Phase 3 trial on Tuesday and hold a conference call to discuss the results The market's expectations for this data have driven up stock prices. Source: The Wall Street Journal. The biopharmaceutical industry has recently performed strongly, with investors optimistic about new drug development. Stocks Ranked Among the Top by Market Capitalization in the Industry Johnson & Johnson rose 0.39%, with a market capitalization of $494.1 billion. Based on recent news, On January 6, Johnson & Johnson announced that its drug nipocalimab for the treatment of systemic lupus erythematosus (SLE) achieved positive top-line results in the Phase 2 JASMINE study. The study met its primary endpoint, showing significant therapeutic effects, and the safety and tolerability were consistent with previous studies. This news boosted investor confidence and drove up the stock price. On January 6, Johnson & Johnson submitted an application to the European Medicines Agency for its drug Teclistamab in combination with Darzalex for the treatment of patients with relapsed/refractory multiple myeloma. This progress demonstrates the company's ongoing efforts in new drug development, further enhancing market expectations for its future growth. On January 6, Johnson & Johnson announced that its drug nipocalimab for the treatment of systemic lupus erythematosus (SLE) showed significant efficacy in Phase 2 studies and plans to initiate Phase 3 clinical trials. This news further solidified the company's leading position in the treatment of immune diseases and boosted the stock price. The healthcare industry has recently performed strongly, with investors optimistic about the progress of new drug development